In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Anti-Thrombotic Therapy - Update 2017

Add to calendar23/02/20170:00 25/02/20170:00 Europe/Paris Anti-Thrombotic Therapy - Update 2017 Working Group on Thrombosis contact@escardio.org true DD/MM/YYYY
Thrombosis, Platelets and Microcirculation
Venous Thromboembolism
Cardiovascular Pharmacology and Pharmacotherapy
Atrial Fibrillation
Invasive and Interventional Cardiology, Cardiovascular Surgery
In-person
event


Watch the webcasts

Scientific programme

Course Directors: Raffaele De Caterina (IT), Erik L. Grove (DK), Steen D. Kristensen (DK), Marco Zimarino (IT)

Faculty: Jean-Philippe Collet (FR), Kurt Huber (AU), David J. Moliterno (USA), Joao Morais (PT), Franz-Josef Neumann (GE), Giuseppe Patti (IT), Bianca Rocca (IT), Helmut Schühlen (GE), Robert F. Storey (UK)

Thursday 23 February

12:30-14:00: Arrival at the European Heart House and Lunch

14:00-14:10: Welcome – R. De Caterina, S.D. Kristensen

SESSION 1: PATHOPHYSIOLOGY AND METHODOLOGY – Chairs: E. Grove and R. De Caterina

Understanding Thrombosis in...
14:10-14:25  Acute Coronary Syndromes – S.D. Kristensen
14:25-14:30  Discussion
14:30-14:45  Venous Thromboembolism – J. Morais
14:45-14:50  Discussion
14:50-15:05  Atrial fibrillation – R. De Caterina
15:05-15:10  Discussion
Methodology
15:10-15:20  Platelet function testing – B. Rocca
15:20-15:30  Evaluating Coagulation – E. Grove
15:30-15:45  Discussion

15:45-16:15  Coffee break    

SESSION 2:  ACS - ACUTE THERAPY (before the cath lab, in the cath lab, and when a cath lab is not available) – Chairs: M. Zimarino and S.D. Kristensen

16:15-16:30  ESC Guidelines: focus on oral antiplatelet therapy before and in the cath lab – S.D. Kristensen
16:30-16:40  Discussion
16:40-16:50  Pretreatment with oral P2Y12 inhibitors in NSTEMI and STEMI - against – J-P. Collet
16:50-17:00  Pretreatment with oral P2Y12 inhibitors in NSTEMI and STEMI - in favour – M. Zimarino
17:00-17:15  Discussion
17.15-17:40  Intravenous antithrombotic agents: bivalirudin, fondaparinux, LMWH, glycoprotein IIb/IIIa inhibitors, cangrelor - D.J. Moliterno
17:40-18:00  Discussion

20:00-22:00  Group Dinner

Friday 24 February

SESSION 3: ACS AFTER THE STORM - ORAL ANTIPLATELET AGENTS – Chairs: D.J. Moliterno and K. Huber

09:00-09:15  ESC Guidelines – drug therapy after the cath lab – J-P. Collet
09:15-09:20  Discussion
09:20-09:35  Duration of DAPT in ACS – R.F. Storey
09:35-09:40  Discussion
09:40-09:55  Thrombin receptor antagonists and other new oral antiplatelet drugs - D.J. Moliterno       
09:55-10:10  Discussion

10:10-10:30  Coffee break

SESSION 4: CORONARY INTERVENTIONS 2017 – Chairs: R. Storey and D.J. Moliterno

10:30-10:45  Thrombectomy – how? For whom? – M. Zimarino
10:45-10:50  Discussion
10:50-11:05  DES or maybe BMS – which one(s)? – H. Schühlen
11:05-11:10  Discussion
11:10-11:25  Bioresorbable stents – for all or for few? – F-J. Neumann
11:25-11:30  Discussion

SESSION 5: STABLE CAD – Chairs: S.D. Kristensen and K. Huber

11:30-11:40  Optimal medical therapy in patients with stable CAD – R.F. Storey
11:40-11:45  Discussion
11:45-11:55  FFR? FFR-CT? Ischaemia testing? – M. Zimarino
11:55-12:00  Discussion
12:00-12:10  Duration of DAPT in Stable CAD after PCI – H. Schühlen
12:10-12:15  Discussion

12:15-16:00  LUNCH AND EXTRAMURAL MEET-THE-EXPERTS SESSION

SESSION 6: NOACs BEYOND ATRIAL FIBRILLATION – Chairs: B. Rocca  and K. Huber

16:00-16:15  The pharmacology of NOACs (including antidotes) – B. Rocca
16:15-16:20  Discussion
16:20-16:35  NOACs in VTE - drug selection according to patient’s risk profile and duration of therapy – J. Morais
16:35-16:40  Discussion
16:40-16:55  NOACs in ACS – R. De Caterina
16:55-17:00  Discussion

17:00-17:15  Coffee break

SESSION 4: ATRIAL FIBRILLATION I – Chairs: J. Morais and B. Rocca

17:15-17:30  Warfarin or NOACs – Lessons from real-life data in different countries – G. Patti
17:30-17:35  Discussion
17:35-17:50  LAA occluders: for whom? – E. Grove
17:50-17:55  Discussion
17:55-18:10  Peri-cardioversion and peri-ablation anticoagulation – G. Patti
18:10-18:25  Discussion

Saturday 25 February

SESSION 8: DIFFICULT CLINICAL CASES – Chairs: M. Zimarino  and E. Grove
The best case will be awarded a prize

09:00-09:15  Case 1 presented by Giampaolo Niccoli
09:15-09:20  Discussion
09:20-09:35  Case 2 presented by Mark Thomas
09:35-09:40  Discussion
09:40-09:55  Case 3 presented by Allan Bohm
09:55-10:00  Discussion
10:00-10:15  Case 4 presented by Giampaolo Niccoli
10:15-10:20  Discussion
10:20-10:25  Voting for the best clinical case

10:25-10:50  Coffee break

SESSION 9: COEXISTING ATRIAL FIBRILLATION AND CAD – Chairs: R. De Caterina and S.D. Kristensen

10:50-11:05  Stable coronary artery disease, elective stenting and atrial fibrillation – K. Huber
11:05-11:10  Discussion
11:10-11:25  After an ACS – R. De Caterina
11:25-11:30  Discussion

11:30-11:40  Best Clinical Case Prize Winner Announcement – E. Grove and M. Zimarino

11:40-11:55  Closing remarks – Course Director

11:45    End of course

Webcasts